Reed Kathrein & Illumina — Holy Grail

Reed Kathrein: Reed Kathrein is a partner at Hagens Berman leading the firm's investigation into Illumina — Holy Grail's trial disclosures. He is a key figure in the firm's efforts to uncover when management knew of the trial's shortcomings.

Illumina — Holy Grail: Illumina — Holy Grail is the defendant in multiple securities fraud class actions. The company's stock collapsed 50.55% after its NHS-Galleri trial failed to meet its primary endpoint, erasing over $2.2 billion in market capitalization. The litigation and trial failure severely damage its financial standing and investor trust.

Reed Kathrein: Reed Kathrein is a partner at Hagens Berman leading the investigation.

Illumina — Holy Grail: Illumina — Holy Grail is the defendant in the securities class action; its stock dropped over 50% after the NHS-Galleri trial failed to meet its primary endpoint, resulting in a $2.2 billion market cap loss.